GlaxoSmithKline PLC
17 June 2002
Directors' Interests
I give below details of changes in directors' interests in the Ordinary Shares
of GlaxoSmithKline plc.
13 June 2002 Abacus (GW) Trustees Limited, as trustee of The
Glaxo Wellcome Employee Trust("the Trust"),
transferred 2,021 Ordinary Shares in the Company
to participants of the Glaxo Wellcome 1999 Long
Term Incentive Plan. The Trust also sold 1,036
Ordinary Shares in the Company at £13.8235 per
share.
The Company was advised of these transactions on 14 June 2002.
The Trust is a discretionary trust of which all employees or former employees of
GlaxoSmithKline Services Unlimited (formerly Glaxo Wellcome plc) and its
subsidiaries are potential beneficiaries. One of the Company's directors, John
Coombe is therefore interested in the shares held in the Trust from time to time
in the same way as other employees or former employees of GlaxoSmithKline
Services Unlimited and its subsidiaries.
S M Bicknell
Company Secretary
17 June 2002
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.